Voyager Therapeutics Q3 2024 Earnings Report
Key Takeaways
Voyager Therapeutics reported increased collaboration revenue and a reduced net loss for the third quarter of 2024. The company's cash position remains strong, providing a runway into 2027.
Licensed TRACERâ„¢ capsid to Novartis in 5th partnered program, receiving $15 million upfront.
Achieved 3rd development candidate in partnership with Neurocrine, triggering a $3 million milestone payment.
Completed enrollment and dosing in the single ascending dose clinical trial of anti-tau antibody VY7523 for Alzheimer’s, with top-line data expected in H1 2025.
Cash, cash equivalents and marketable securities were $345.4 million as of September 30, 2024.
Voyager Therapeutics
Voyager Therapeutics
Voyager Therapeutics Revenue by Segment
Forward Guidance
Voyager expects its cash, cash equivalents, and marketable securities, along with amounts expected to be received as reimbursement for development costs under the Neurocrine and Novartis collaborations and interest income, to be sufficient to meet Voyager’s planned operating expenses and capital expenditure requirements into 2027.